View Older Stories
-
Citi keeps Sell rating on Moderna after melanoma trial data, PT $80
-
Merck and Moderna report Phase 3 melanoma trial results
-
Moderna (MRNA) call put ratio 1 call to 1.6 puts as share price down 22%
-
Moderna shares plunge on cancer vaccine data leak
-
Merck & Co Inc: Intismeran Plus Keytruda Significantly Reduced The Risk Of Recurrence Or Death By 42% Compared To Keytruda Alone - Reuters
-
Moderna now down 20% amid alleged data leak selloff
-
Moderna Shares Tumble 16% After Alleged Leak of Melanoma Vaccine Data
-
Moderna (MRNA) Halted on Volatility, down 11.86%
-
Moderna (MRNA) on Watch Following Chatter of Positive Data
-
Moderna (MRNA) PT Raised to $90 at TD Cowen
-
Moderna shares rise ahead of cancer vaccine trial results
-
U.S. biotech SMids: Q3 earnings preview
-
RBC: 'ESMO is likely the biggest event for MRK/MRNA for the rest of this year'
-
Moderna shares fall amid valuation concerns
-
Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
-
Tempus expands collaboration with Moderna and Merck on cancer therapy
-
Novavax and Moderna shares fall after plague concerns ease, Citi comments
-
Moderna to join the Nasdaq-100 index, replacing Warner Bros. Discovery
-
Moderna (MRNA) call put ratio 1 call to 1.1 puts amid wide price movement
-
Moderna: Citi says oncology optimism is priced in, cuts rating to sell
-
Moderna names Juan Andres as COO amid oncology expansion
-
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
-
Moderna (MRNA) call put ratio 1.4 calls to 1 put into share price lower before the bell
-
Citi downgrades Moderna to Sell, sets $80 price target
-
Bernstein SocGen Reiterates Market Perform Rating on Moderna (MRNA)
-
UBS Reiterates Neutral Rating on Moderna (MRNA)
-
Moderna to present mRNA cancer therapy data at ESMO 2026
-
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
-
Moderna shares climb on cancer vaccine momentum
-
Moderna (MRNA) spreader of 1K contracts of September 25 weekly 157.50 and 165 calls as share price up 10.5%
-
Moderna shares gain on momentum and short squeeze
-
Rothschild Redburn Downgrades Moderna (MRNA) to Sell
-
Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
-
Moderna to Present at Upcoming Conferences in September 2026
-
Argus Upgrades Moderna (MRNA) to Buy
-
Moderna prices $2.6B convertible notes offering due 2032
-
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
-
FDA approves Moderna's updated 2026-2027 COVID-19 vaccines
-
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
-
Moderna plans $2B convertible notes offering due 2032
-
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
-
Wolfe Research Upgrades Moderna (MRNA) to Peerperform
-
Active options: MRNA SOFI BABA INTC MARA META COIN AMD GOOGL MSFT WMT
-
Moderna (MRNA) call put ratio 1.1 calls to 1 put amid sharp rally
-
Moderna stock pulls back after massive one-day rally: analysts weigh in
-
Guggenheim Reiterates Buy Rating on Merck (MRK)
-
Moderna (MRNA) call put ratio 1 calls to 2.1 puts amid wide price movement
-
Moderna (MRNA) PT Raised to $89 at Morgan Stanley
-
Morgan Stanley Upgrades Merck (MRK) to Overweight
-
Active options: MRNA AMD AVGO PLTR GOOGL NFLX PFE SOFI NBIS COIN


